This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Induced abortion
  • /
  • Letrozole pre-treatment prior to medical terminati...

Letrozole pre-treatment prior to medical termination of pregnancy: a systematic review.

Read time: 1 mins
Published:14th Nov 2017
Author: Nash CM, Philp L, Shah P, Murphy KE.
Source: Contraception
Availability: Pay for access, or by subscription
Ref.:Contraception. 2017. pii: S0010-7824(17)30520-6.

Objective(s): The purpose of this systematic review was to evaluate the efficacy of pretreatment with letrozole prior to either a first or second trimester medical termination of pregnancy.

Study design: We searched letrozole, femara, aromatase inhibitors, abortifacient agents, termination of pregnancy, and labour induction in MEDLINE, EMBASE, Cochrane Database, Google Scholar, and PubMed from inception of each database until September 2015 with no language limitation. A systematic review of all randomized controlled trials (RCTs) was performed where women received either letrozole and misoprostol or placebo and misoprostol for termination of pregnancy. The primary outcome was complete abortion rate, defined as complete evacuation of the products of conception from the uterus. Relative risk (RR) with 95% confidence intervals was used to report data.

Results: Our systematic review identified 7 studies; 4 RCTs were included in the review. Two RCTs evaluated terminations of pregnancy up to 9weeks gestation, while 2 evaluated terminations over 9weeks gestation. For each gestational age group, one trial supported an increase in complete abortion rate, while the other showed no difference, with letrozole and misoprostol compared with placebo and misoprostol. Time-to-abortion interval for terminations up to 9weeks gestation was not improved with the addition of letrozole to misoprostol. For terminations over 9weeks gestation, one trial supported and one trial refuted a decrease in time-to-abortion interval with letrozole and misoprostol. Similarly, for each gestational age group, one study supported a decrease and one study showed no difference in rate of D&C with letrozole and misoprosol. Medication side-effects were similar between both treatment groups. There was significant heterogeneity between the trials and, therefore, the results were not meta-analyzed.

Conclusion(s): Some studies and trials report better outcomes (i.e. complete abortion rates, time-to-abortion, and D&C rates) in women exposed to letrozole and misoprostol compared to placebo and misoprostol, while other trials demonstrate no difference. Further research exploring letrozole pre-treatment prior to medical abortion is required.

Implications: This systematic review demonstrated that a combination of letrozole and misoprostol increased the rate of complete abortion compared to misoprostol alone in some studies, but not in others; additional well designed RCT's are needed.

Read abstract on library site

Access full article